





IMPACT OF HYDROXYPROPYL METHYLCELLULOSE (HPMC) TYPE AND CONCENTRATION ON 
THE SWELLING AND RELEASE PROPERTIES OF PROPRANOLOL HYDROCHLORIDE MATRIX 
TABLETS USNING A SIMPLEX CENTROID DESIGN 
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ABSTRACT 
Objective: To prepare hydroxypropyl methylcellulose (HPMC) matrix tablets of propranolol hydrochloride (PNL) using a simplex centroid design. 
Methods: HPMC matrix tablets with different amounts and types of HPMC were prepared by direct compression. A simplex centroid design was 
used to evaluate tablet weight (Y
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1), thickness (Y2), hardness (Y3), axial swelling time at 0.5–12 h (Y4-Y9), radial swelling time at 0.5–12 h (Y10-Y15), 
and % released at 1–12 h (Y16-Y19). 
Results: The tablet weight, thickness, and hardness were 397.6–400.4 mg, 3.967–4.029 mm, and 106.9–139.0 N, respectively. The % swelling (axial) 
and % swelling (radial) 
Keywords: Hydroxypropyl methylcellulose (HPMC), Matrix tablets, Simplex centroid design, Design of experiment, Propranolol hydrochloride, 
Swelling, Release mechanism 
at 0.5–12 h were-8.715 to 59.889 and-1.887 to 49.287, respectively. The negative % swelling could be attributed to erosion of 
the tablets. The in vitro release of PNL from the tablets in buffer solution pH 1.2 (1 h) and pH 7.5 (3–12 h) was 21.12–76.22%. Tables with a high 
proportion of K100M HPMC had high PNL release, and the mechanism of PNL release was diffusion-and erosion-controlled. 
Conclusion: The simplex centroid design is potentially advantageous for formulating PNL-HPMC matrix tablets. 




The tablet dosage form is an extensively used oral administration 
route, as it is easy to handle, easy to manufacture, economical, and 
has good stability and painless administration when compared with 
other pharmaceutical routes [1]. However, the drug release rate 
cannot be controlled with conventional tablets, leading to the risk of 
toxicity due to dose dumping, and some drugs require several doses 
daily to sustain therapeutic levels in the bloodstream [2]. This issue 
is resolved with oral controlled-release dosage forms, and one 
interesting selection in this system is the hydrophilic polymer 
matrix. This matrix is very popular for prolonging drug release 
because it is easy and economical to manufacture, has high 
reproducibility, good stability, increases patient compliance, and 
decreases incidences of drug toxicity from dose dumping [3-5]. The 
drug release mechanisms of the hydrophilic polymer matrix 
generally involve three steps: dissolution, diffusion through swelling 
polymers, and erosion [6-8]. Hence, the hydrated gel layer of the 
matrix is formed by hydrophilic polymer swelling after interaction 
with water. This layer is a crucial influencing factor of the control of 
drug release from the matrix [3, 7]. Moreover, hydrophilic polymer 
type and concentration also affect gel layer formation and the drug 
release rate of matrix tablets, and an interesting choice of 
hydrophilic polymer is hydroxypropyl methylcellulose (HPMC). 
HPMC is an extensive hydrophilic polymer used in many 
pharmaceutical dosage forms, including as a hydrophilic matrix form 
with prolonged drug release [4, 9]. HPMC has many advantages such 
as ease of use and compression, high levels of drug loading, stability 
at a wide range of pH, and rapid swelling [4, 9-11]. There are several 
grades of HPMC based on the molecular weight, methoxy group 
content percentage (-OCH3), and hydroxypropoxy group percentage 
(-OCH2CH (OH) CH3
6
) of the molecular structure, resulting in 
different HPMC viscosities and physical properties [ , 8]. Bose et al. 
used three ratios of various HPMC grades to formulate matrix 
tablets, and found that altering the ratios of the HPMC grades could 
control the drug release rate from the matrix [6]. Additionally, many 
researchers use HPMC for preparing extended-release tablets of 
various model drugs such as itopride, hydrocortisone, theophylline, 
propranolol, and isoniazid [2, 5, 6, 12]. 
Propranolol hydrochloride (PNL), a β-adrenergic blocking agent, is 
commonly used for treating hypertension, angina pectoris, and 
cardiac arrhythmia [2, 4, 10]. Normally, the conventional tablet form 
PNL has to be taken three or four daily to maintain drug levels in the 
bloodstream within the therapeutic range, as its half-life in the 
circulation is short [10, 13]. After oral administration, PNL can be 
absorbed entirely through the gastrointestinal tract membrane, but 
only 25–30% bioavailability is achieved due to the hepatic first-pass 
effect [2, 10]. Thus, hydrophilic polymer matrix tablets may be a 
suitable dosage form for reducing the number of doses taken in one 
day and helps improve patient compliance. 
The traditional trial-and-error method of formulating matrix tablets has 
many disadvantages such as being time-consuming, laborious, 
expensive, and unpredictable [2, 14]. Therefore, design of experiment 
(DOE) is used to resolve the problems encountered with the traditional 
method and is useful for manipulating complex formulations or 
formulations that involve many variables [14, 15]. Based on these 
rationales, DOE is an interesting technique and has been widely used for 
many pharmaceutical dosage forms [1, 2, 6, 14, 16]. 
The present study used the simplex centroid design DOE to evaluate 
the effect of HPMC concentration and type on the weight, thickness, 
hardness, % swelling, and % release of PNL from HPMC matrix 
tablets. Therefore, the objective was to prepare HPMC matrix tablets 
of PNL using a simplex centroid design approach. 
MATERIALS AND METHODS 
Materials 
K4M (H-K4M), K15M (H-K15M), and K100M HPMC (H-K100M) 
(Methocel®) were manufactured by Dow Chemical Company 
(Midland, MI, USA) and kindly supported by Rama Production Co., 
Ltd. (Bangkok, Thailand). Propranolol HCl was purchased from PC 
Drug Co. Ltd. (Bangkok, Thailand). All other chemicals used were of 
analytical grade and were used as received. 
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Preparation of HPMC matrix tablets 
Direct compression was used to prepare HPMC matrix tablets 
containing different amounts and types of HPMC (table 1). First, 
accurate amounts of PNL, HPMC, microcrystalline cellulose and 
dihydrate dibasic calcium phosphate were mixed using mortar and 
pestle until the compounds were uniform. The other ingredients were 
added and manually blended in a polybag for 5 min. The mixture was 
compressed using a hydraulic press (Model 15011, Specac, Fort 
Washington, PA, USA) with a 9.5-mm diameter flat-faced punch at a 
compression force of 1 ton and a dwell time of 10 seconds. The tablets 
were stored in a vacuum desiccator before testing. 
 
Table 1: The simplex centroid design of HPMC matrix tablets 
Formulation An actual value of independent factors 
H-K4M (mg), (X1 H-K15M (mg), (X) 2 H-K100M (mg), (X) 3) 
T1 0 0 60 
T2 0 30 30 
T3 0 60 0 
T4 10 10 40 
T5 10 40 10 
T6 20 20 20 
T7 30 0 30 
T8 30 30 0 
T9 40 10 10 
T10 60 0 0 
T11 60 0 0 
 
Simplex centroid design and statistical analysis 
A simplex centroid design was used to evaluate the effect of HPMC 
concentration and type on the tablet weight, thickness, hardness, % 
swelling, and % release. The tablet formulation components are 
shown in table 1. The three main ingredients, namely H-K4M (X1), H-
K15M (X2), and H-K100M (X3), were identified as casual factors. The 
upper and lower limits of each component were set as follows:  
0 ≤ X1≤100 (%)……… (1) 
0 ≤ X2 ≤100 (%)……. (2) 
0 ≤ X3 ≤100 (%)……. (3) 
X1+X2+X3= 100 (%)……. (4) 
X1+X2+X3= 60.0 (mg)……. (5) 
The three main ingredients of the tablet formulations were changed 
concurrently and the whole amount was adjusted to 100% (60 mg). 
The tablet characteristics, i.e., weight (Y1), thickness (Y2), hardness 
(Y3), axial swelling time at 0.5–12 h (Y4-Y9), radial swelling time at 
0.5–12 h (Y10-Y15), and % released at 1–12 h (Y16-Y19) were defined 
as dependent variables. Design-Expert®
The swelling and erosion behavior of the tablets was determined by 
optical observation, where tablets were submerged in dissolution 
media; the method was modified from a previously reported method 
in Nunthanid et al. [
 software (version 9; Stat-
Ease, Inc., Minneapolis, MN, USA) was used to estimate the 
responses of all model tablets. A total of 11 random runs, three 
levels, and three factors were planned by the software, and the 
setting variables were used as required. Analysis of variance 
(ANOVA) was used for the statistical analysis. 
Characterization of HPMC matrix tablets 
Three physical properties (weight, thickness, hardness) of the 
tablets were examined at room temperature (ca. 25 °C). Each tablet 
was weighed using a weighing machine (AC 210 S, Sartorius, 
Göttingen, Germany) for computing the weight variation (n=20). The 
thickness and hardness of 10 tablets were inspected simultaneously 
using thickness and hardness tester (TBH 225 TD, ERWEKA, 
Heusenstamm, Germany). 
Swelling behavior of HPMC matrix tablets 
17]. This method has an advantage over the 
gravimetric technique because there is no interruption from error of 
wiping excess medium from the samples during weighing. In 
addition, all data from this method are real-time and obtained in situ 
[17]. For the radial swelling test, each tablet was fixed to a petri dish 
with double-sided adhesive tape, and buffer solution (pH 1.2, 
containing 2 g NaCl and 7.0 ml HCl per liter distilled water adjusted 
to pH 1.2 with NaOH or HCl) was added at 0.5 h and 1 h. After 1 h, 
the test medium was carefully removed and changed to buffer 
solution (pH 7.5, containing 6.8 g KH2PO4
% Swelling
 and 1.6 g NaOH per liter 
distilled water adjusted to pH 7.5 with NaOH or HCl) at 2,3,6, and 12 
h. For the axial swelling test, open-ended tubes with the same 
diameter as the tablets were modified to observe the axial swelling. 
The medium and predetermined times of axial swelling were as 
described in the radial swelling test. Each swelling test was 
performed in quadruplicate, and the % swelling was calculated using 










× 100……. (7) 
ο and Hο are the upper surface area (π(Dο 2)⁄ , Dο is tablet 
diameter) and thickness of the initial dry tablet, respectively. At and 
Ht are the upper surface area and thickness of the radial and axial 
swelling of the tablet at time t, respectively. 
In vitro release of HPMC matrix tablets 
The release of PNL from the tablets was investigated using the United 
States Pharmacopeia (USP) Dissolution Test 2 of PNL extended-release 
capsules (basket method, 50 rpm). Buffer solution (900 ml, pH 1.2) in 
each vessel was used as the dissolution medium in the first hour and 
maintained at 37 °C. The release medium (5 ml) was removed, and 
then the entire medium was removed. Next, the same amount of buffer 
solution (pH 7.5) as the previous medium was added, 5 ml release 
medium was removed at 3, 6, and 12 h, and an equal volume of fresh 
medium was replaced at each time. The amount of PNL was analyzed 
using spectrophotometry at 320 nm (Agilent, model 1100 series, Santa 
Clara, CA, USA). Six tablets per formulation were used and the 
percentage PNL released was calculated. 
Release data analysis 
The drug release kinetics of the tablets was matched with zero-
order, first-order, Higuchi, and Korsmeyer–Peppas equations 
(Eqs.8–11, respectively), as follows:  
Q = Q0+K0t ………. (8) 
Log Q = log Q0-K1t/2.303……… (9) 
Q = Kht1/2………. (10) 
Mt/Mα  = Ktn
where Q is the cumulative amount of drug release at time (t), 
M
………. (11) 
t/Mαthe fractional drug release at time (t), t the time in hours, Q0 the 
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initial amount of drug in the solution, K0 the zero-order release 
constant, K1 the first-order release constant, Kh the Higuchi constant, K 
the Korsmeyer–Peppas constant, and n the release exponent indicative 
of the drug release mechanism. The value of n was used to predict the 
drug release mechanism, and a maximum R2
RESULTS AND DISCUSSION 
 of each equation was 
used to select the appropriate mathematical release model. 
Characterization of HPMC matrix tablets 
Direct compression was used to prepare HPMC matrix tablets with 
different types and amounts of HPMC. Physical factors such as 
weight, thickness, and hardness affect the swelling properties and 
release of drugs from tablets. Consequently, these factors should be 
considered when preparing tablets. Fig. 1 shows the contour plot of 
the effect of the amount and type of HPMC on the physical properties 
of the tablets. The tablets weighed 397.6–400.4 mg and displayed 
only green areas in the contour plot (fig. 1A). From the result, it can 
be assumed that the concentrations of the various HPMC types did 
not significantly influence the tablet weight. The small variation in 
tablet weights may have been due to the use of a manual hydraulic 
press for weighing and compressing each tablet individually. The 
tablet is shown in fig. 1B and was 3.967–4.029 mm thick. The highest 
thickness could be seen only for tablets containing H-K15M (red 
color in the contour plot), but was not significant (p>0.05). The 
hardness of the tablets ranged 106.9–139.0 N (fig. 1C). The high 
hardness value could be observed only in tablets with large 
proportions of H-K4M and H-K100M. This could be explained by 
particle size, in that the tablet hardness decreased as the particle 
size of the compound increased [7]. A previous report demonstrated 
the particle size and size distribution of HPMC K-series and 
suggested that H-K100M had considerably smaller particle size than 
other-grade HPMC, and involved slightly narrower size distribution 
[18]. However, the hardness contour plot showed a small blue area 
at the corner denoting H-K100M, referring to low hardness when the 
tablet formulation contained only H-K100M. Hence, the high 
hardness value may have been due to particle-particle interactions 
of suitable ratios of H-K4M and H-K100M [18]. 
The corresponding residual plot was used to check the reliability of 
the response variables. They are displayed in fig. 1D, 1E, and 1F, 
which were plotted between the run number and the internally 
studentized residuals of Y1, Y2, and Y3
 
Fig. 1: Contour plots of HPMC matrix tablets for weight (A, Y
, respectively. In the fully 
randomized run, the vertical expansion of the internally studentized 
residuals was in line from bottom to top, indicating that all data 
points lay within the limits of a 95% confidence interval. 
 
1), thickness (B, Y2), hardness (C, Y3) and the corresponding residual plot 
between run number and internally studentized residuals for weight (D, Y1), thickness (E, Y2) and hardness (F, Y3
 
Swelling behavior of HPMC matrix tablets 
) 
Many researchers have reported the swelling properties of matrix 
tablets because they play a crucial role in drug release from the 
tablets [7, 17, 19]. The polymer-polymer and polymer–solvent 
interactions are major controlling factors of swelling and erosion 
[20]. When the media comes into contact with the tablets and water 
penetrates the tablets, consequently causing hydration, swelling, gel 
formation, and erosion may occur in parallel at the interface of the 
tablets. The swelling medium in the present study was the 
progressive pH medium. It comprised buffer solution (pH 1.2) in the 
first 1 h, and was subsequently changed to a buffer solution (pH 7.5) 
and maintained for the following 12 h. The axial swelling 
illustrations and contour plot of % swelling (axial)  are shown in fig. 2 
and fig. 3, respectively. The % swelling (axial)  at0.5–12 h was-8.715 to 
59.889, and the negative % swelling (axial)
20
 could be attributed to 
erosion of the tablets. The erosion in the first time period (0.5 h and 
1 h) was highest in tablets with high amounts of H-K100M (fig. 3A 
and 3B). The result correlated with the axial swelling fig. for the T1 
and T4 formulations, in that there was more eroded powder around 
the tablets compared to the other formulations (fig. 2). Conversely, 
tablets with high amounts of H-K100M had more axial swelling than 
tablets of the other formulations at 6 and 12 h. These appearances 
may be described in that in the first time period of axial swelling, the 
erosion rate of tablets with high amounts of high–molecular weight 
HPMC (H-K100M) was higher than the rate of swelling [ ], but at a 
later time period, tablets with the highest–molecular weight HPMC 
had greater swelling rates than erosion rates [7]. Additionally, 
another report indicated that the higher–molecular weight HPMC 
type-K leads to increased contact angle between the HPMC surface 
and distilled water, exhibiting more hydrophobicity [21]. Hence, in 
equal concentrations, H-K100M was more hydrophobic than H-K4M 
and H-K15M, reducing the amount of water penetrating the tablets 
and decreasing swelling [9]. The axial swelling during the final time 
period could be explained by the polymer chain entanglement [5, 
21], which involves the viscosity of the polymer. At the same 
amount, H-K100M has higher viscosity than other HPMC K-types, 
constructing larger structural chain entanglement than low-viscosity 
HPMC [5, 21]. Thus, it is difficult for high–molecular weight HPMC to 
dissolve due to the high energy needed to remove them fromthe 
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tablets [5]. Then, following hydration in the last time period, tablets 
with H-K100M had more swelling than that with other HPMC types. 
Only the green area in the contour plot in fig. 3D suggested no 
significant difference in the effect of HPMC amount and molecular 
weight on axial swelling at hour 3. Axial swelling at hour 6–12 had 
different contour plot patterns from the early period, in that high 
amounts of low–molecular weight HPMC resulted in less swelling 
than higher amounts of high–molecular weight HPMC. This result 
correlates with another article reporting higher swelling of high–
molecular weight polymers used for preparing matrix tablets than 
low–molecular weight polymers [7]. 
 
 
Fig. 2: Axial swelling behavior of HPMC matrix tablets at various times (Y4-Y9
 
Fig. 3: Contour plots of HPMC matrix tablets for (%) axial swelling at 0.5 h (A, Y
) 
 
4), 1 h (B, Y5), 2 h (C, Y6), 3 h (D, Y7), 6 h (E, Y8) and 12 h (F, Y9
 
) 
The radial swelling fig. and contour plot of % swelling (radial)  are 
shown in fig. 4 and fig. 5, respectively. The % swelling (radial)  at 0.5–12 
h was-1.887 to 49.287, and the final value of radial swelling was 
lower than that of axial swelling. The radial swelling of the tablets 
containing different concentrations of HPMC at 0.5 h and 1h were 
quite similar, and there was little erosion. However, tablet erosion 
was observed at hour 12 of radial swelling in the tablets with high 
amounts of H-K4M, i.e., the T9 and T10 formulations (fig. 4). This 
supports the reason above explaining why low–molecular weight 
HPMC swells less than high–molecular weight HPMC; conversely, it 
had a higher erosion rate than the high–molecular weight HPMC. At 
hour 2 of radial swelling, the obvious red area of the contour plot in 
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fig. 5C shows the high swelling of the tablets containing high H-K4M 
and H-K100M ratios. At these concentrations, the swelling could not 
be sustained until the end of the experiment at hour 12. At hour 12, 
high swelling could be observed in the tablets with high H-K4M and 
H-K15M ratios; conversely, tablets with high H-K4M and H-K100M 
ratios became erodedat this point, as described earlier. Therefore, 
the different equilibrium swelling time of the tablets depends on the 
HPMC ratios and molecular weights. 
The reliability of the response variable was ensured by operating 
with the corresponding residual plot. Fig. 6 and 7 show the graph 
plotted between the run number and the internally studentized 
residuals of axial (Y4-Y9) and radial swelling (Y10-Y15
 
Fig. 4: Radial swelling behavior of HPMC matrix tablets at various times (Y
), respectively, 
at the various time points. In the throughly randomized run, the 
vertical expansion of the internally studentized residuals was in line 
from bottom to top, indicating that all data points lay within the 




Fig. 5: Contour plots of HPMC matrix tablets for (%) radial swelling at 0.5 h (A, Y
) 
 
10), 1 h (B, Y11), 2 h (C, Y12), 3 h (D, Y13), 6 h (E, Y14) and 12 
h (F, Y15) 
 
Kraisit 




Fig. 6: The corresponding residual plot between run number and internally studentized residuals for (%) axial swelling of HPMC matrix 
tablets at 0.5 h (A, Y4), 1 h (B, Y5), 2 h (C, Y6), 3 h (D, Y7), 6 h (E, Y8) and 12 h (F, Y9
 
Fig. 7: The corresponding residual plot between run number and internally studentized residuals for (%) radial swelling of HPMC matrix 
tablets at 0.5 h (A, Y
) 
 
10), 1 h (B, Y11), 2 h (C, Y12), 3 h (D, Y13), 6 h (E, Y14) and 12 h (F, Y15
 
In vitro release of HPMC matrix tablets and drug release kinetics 
) 
The contour plot for the in vitro release of PNL from the tablets in 
buffer solution at pH 1.2 (1 h) and pH 7.5 (3–12 h) was 21.12–
76.22% (fig. 8). Therefore, the various HPMC molecular weights and 
concentrations could significantly impede the release rate of PNL 
from the tablet until hour 12. The PNL release patterns at different 
HPMC ratios and molecular weights were quite similar in the 1–6-h 
period. Tablets with a high proportion of H-K100M had greaterPNL 
release, shown as yellow or orange areas in the contour plot. 
Typically, any polymer with a higher molecular weight results in a 
decreased release rate due to the stronger gel barrier [3, 9]. These 
authors described the swelling property of polymers, where 
polymers with high molecular weights led to greater matrix 
swelling, leading to the reduced release rate of the model drug. 
However, it was difficult to clarify our results with only the swelling 
property, as it does not only depend on the molecular weight of the 
HPMC but also the duration the tablets were submerged in the 
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experimental media. Other reports correlate with our result and 
clarify that the high release of high–molecular weight polymer may 
be due to the faster disintegration of the tablets [22]. In addition, the 
different HPMC molecular weights may have little influence on drug 
release because soluble drugs can dissolve quickly in water or acidic 
and basic medium before complete swelling occurs [12]. Therefore, 
we may summarize that the HPMC concentration and molecular 
weight crucially influence the release rate of PNL from the tablets, 
such that extended-release tablets can be formulated by modifying 
the HPMC concentrations and molecular weights as appropriate. 
Table 2 shows the mathematical release models of the HPMC matrix 
tablets. The fitting models selected for the release pattern were 
zero-order, first-order, Higuchi, and Korsmeyer–Peppas models. In 
the present study, all formulations showed a good fit with the 
Korsmeyer–Peppas model, as it showed a maximum correlation 
coefficient (R2
3
), indicating that the mechanism of PNL release from 
the tablets was diffusion-and erosion-controlled [ , 23]. The release 
exponent values (n) of the present study (cylindrical shape) were 
around 0.45, indicating classical Fickian diffusion–controlled drug 
release [8, 13, 23]. In addition, the axial and radial swelling study 
support this release mechanism, in that tablet erosion and swelling 
were observed for all formulations. Therefore, the release patterns 
of the HPMC matrix tablets fit ting the Korsmeyer–Peppas model 
propose drug release by diffusion and erosion. 
Fig. 8 shows that the suitable model was analyzed by comparing run 
number versus internally studentized residuals, and showed that the 
data points fellwithin the limits. 
 
 
Fig. 8: Contour plots of the in vitro release of PNL from HPMC matrix tablets at 1 h (A, Y16), 3 h (B, Y17), 6 h (C, Y18), 12 h (D, Y19) and the 
corresponding residual plot between run number and internally studentized residuals for the in vitro release at 1 h (E, Y16), 3 h (F, Y17), 6 
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Table 2: In vitro release kinetics of PNL from HPMC matrix tablets 
Formulation Mathematical release models 




Koresmeyer-peppas release exponent (n) 
) 
T1 0.7747 0.9265 0.9652 0.9866 0.3645 
T2 0.8590 0.9629 0.9940 0.9988 0.4341 
T3 0.8762 0.9709 0.9973 0.9996 0.4529 
T4 0.8160 0.9374 0.9820 0.9950 0.4001 
T5 0.8583 0.9574 0.9939 0.9972 0.4493 
T6 0.8640 0.9618 0.9945 0.9949 0.4709 
T7 0.8241 0.9402 0.9844 0.9920 0.4190 
T8 0.8546 0.9608 0.9932 0.9986 0.4338 
T9 0.8830 0.9736 0.9980 0.9978 0.4859 
T10 0.8536 0.9564 0.9928 0.9965 0.4453 
 
CONCLUSION 
The simplex centroid design was used to evaluate the effect of 
HPMC concentration and type on the weight, thickness, hardness, 
% swelling, and % release of PNL from HPMC matrix tablets. The 
tablets were prepared by direct compression. The HPMC 
concentrations did not influence the tablet weight significantly. 
The highest thickness was observed only for tablets containing H-
K15M, but was not significant. High hardness values were 
observed only in tablets with high H-K4M and H-K100M ratios. 
The different equilibrium swelling time of the tablets depended on 
the HPMC ratios and molecular weights. Tablets with high 
proportions of H-K100M had greater PNL release, and the 
mechanism of PNL release from the tablets was diffusion-and 
erosion-controlled. Therefore, the simplex centroid design is 
potentially advantageous for formulating HPMC matrix tablets of 
PNL. 
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